These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 38703335)
1. The cuproptosis-related gene UBE2D2 functions as an immunotherapeutic and prognostic biomarker in pan-cancer. Fei Y; Cao D; Dong R; Li Y; Wang Z; Gao P; Zhu M; Wang X; Zuo X; Cai J Clin Transl Oncol; 2024 Oct; 26(10):2718-2737. PubMed ID: 38703335 [TBL] [Abstract][Full Text] [Related]
2. Comprehensive pan-cancer analysis of CD73: Explore its association with prognosis and tumor immune microenvironment. Chen C; Liu S; Ma Y Heliyon; 2024 Nov; 10(22):e40329. PubMed ID: 39624281 [TBL] [Abstract][Full Text] [Related]
3. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer. Yin HZ; Zhang MC; Wu H Biochem Genet; 2024 Dec; 62(6):4335-4358. PubMed ID: 38296907 [TBL] [Abstract][Full Text] [Related]
4. Prognosis and immune landscape of bladder cancer can be predicted using a novel miRNA signature associated with cuproptosis. Zhang Z; Liu F; Yu Y; Xie F; Zhu T PeerJ; 2024; 12():e18530. PubMed ID: 39624133 [TBL] [Abstract][Full Text] [Related]
5. Role of CALCR expression in liver cancer: Implications for the immunotherapy response. Wang S; Wang W; Zeng J Mol Med Rep; 2025 Feb; 31(2):. PubMed ID: 39611512 [TBL] [Abstract][Full Text] [Related]
6. Deciphering potential molecular mechanisms in clear cell renal cell carcinoma based on the ubiquitin-conjugating enzyme E2 related genes: Identifying UBE2C correlates to infiltration of regulatory T cells. Feng X; Wang Z; Cen M; Zheng Z; Wang B; Zhao Z; Zhong Z; Zou Y; Lv Q; Li S; Huang L; Huang H; Qiu X Biofactors; 2025; 51(1):e2143. PubMed ID: 39614426 [TBL] [Abstract][Full Text] [Related]
7. Comprehensive pan-cancer analysis reveals prognostic implications of TMEM92 in the tumor immune microenvironment. Wu Z; Pan T; Li W; Zhang YH; Guo SH; Liu Y; Zhang L; Wang ZY Clin Transl Oncol; 2024 Oct; 26(10):2701-2717. PubMed ID: 38642258 [TBL] [Abstract][Full Text] [Related]
8. The Potential of ESCO2 as a Prognostic and Immunotherapeutic Marker of Pan-Cancer and Its Role in Anti-PD-1 Treatment of Bladder Cancer. Guo W; Zhao S; Yan K; Fan Y; Liu J Oncology; 2024 Nov; ():1-18. PubMed ID: 39527939 [TBL] [Abstract][Full Text] [Related]
9. Overexpression of ELF1 combined with MMP9 is associated with prognosis and tumor microenvironment in gastric cancer. Zhang X; Ren X; Zhang S; Wang Y Exp Ther Med; 2024 Dec; 28(6):441. PubMed ID: 39583246 [TBL] [Abstract][Full Text] [Related]
10. Pan-Cancer Analysis of P3H1 and Experimental Validation in Renal Clear Cell Carcinoma. Li Y; Wang T; Jiang F Appl Biochem Biotechnol; 2024 Sep; 196(9):5974-5993. PubMed ID: 38175417 [TBL] [Abstract][Full Text] [Related]
11. Pyroptosis-related long-noncoding RNA signature predicting survival and immunotherapy efficacy in patients with lung squamous cell carcinoma. Zhan X; Li J; Ding Y; Zhou F; Zeng R; Lei L; Zhang Y; Feng A; Qu Y; Yang Z Clin Exp Med; 2024 Jul; 24(1):145. PubMed ID: 38960987 [TBL] [Abstract][Full Text] [Related]
12. Identification of CAPG as a potential prognostic biomarker associated with immune cell infiltration and ferroptosis in uterine corpus endometrial carcinoma. Liu J; Zhu W; Xia L; Zhu Q; Mao Y; Shen Y; Li M; Zhang Z; Du J Front Endocrinol (Lausanne); 2024; 15():1452219. PubMed ID: 39600941 [TBL] [Abstract][Full Text] [Related]
13. Pan-Cancer Analysis of PTBP1 to Identify it as a Prognostic and Immunological Biomarker. Zhao Y; Wang Y; Xia Q; He H; Mao Q; Dong H; Zhu L; Hu Z; Xia J; Weng Z; Liao W; Xin Z Cancer Control; 2024; 31():10732748241302865. PubMed ID: 39612472 [TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma. Gong W; Zhang S; Tian X; Chen W; He Y; Chen L; Ding T; Ren P; Shi L; Wu Q; Sun Y; Chen L; Guo H Hepatol Int; 2024 Aug; 18(4):1310-1325. PubMed ID: 38767772 [TBL] [Abstract][Full Text] [Related]
15. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone. Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924 [TBL] [Abstract][Full Text] [Related]
16. Identifying an Inversin as a Novel Prognostic Marker in Patients with Clear-Cell Renal Cell Carcinoma. Urlić I; Šoljić V; Vukoja M; Marijanović I; Kraljević M; Urlić M; Marić S; Vukojević K; Filipović N Int J Mol Sci; 2024 Nov; 25(22):. PubMed ID: 39596188 [TBL] [Abstract][Full Text] [Related]
17. The prognostic significance and immune characteristics of bone morphogenetic proteins (BMPs) family: A pan-cancer multi-omics analysis. Chen C; Zhang Y; Lin Y; Shen C; Zhang Z; Wu Z; Qie Y; Zhao G; Hu H Technol Health Care; 2024; 32(6):4123-4175. PubMed ID: 39031404 [TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-Specific Protease 52 as a Prognostic Biomarker Correlates with Tumor Microenvironment and Therapy Response in Colorectal Cancer. Zhou J; Nie H; Yang X; Wang F; Yu P; Yu Y; Ning Y; Lai J; Wang H; Zhao Q; Xu F Oncology; 2024; 102(12):1041-1055. PubMed ID: 39047691 [TBL] [Abstract][Full Text] [Related]
19. Single-cell and Bulk Transcriptomic Analyses Reveal a Stemness and Circadian Rhythm Disturbance-related Signature Predicting Clinical Outcome and Immunotherapy Response in Hepatocellular Carcinoma. Zhu X; Zhang Z; Zhang J; Xiao Y; Wang H; Wang M; Jiang M; Xu Y Curr Gene Ther; 2025; 25(2):178-193. PubMed ID: 38847249 [TBL] [Abstract][Full Text] [Related]